MELBOURNE, Australia and NEW YORK, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the Phase 2 clinical trial using the Company’s proprietary Mesenchymal Precursor Cells (MPCs) for lumbar spinal fusion has been selected for presentation at the North American Spine Society (NASS) 28th Annual Meeting.
Help employers find you! Check out all the jobs and post your resume.
